• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
Catholic Review

Catholic Review

Inspiring the Archdiocese of Baltimore

Menu
  • Home
  • News
        • Local News
        • World News
        • Vatican News
        • Obituaries
        • Featured Video
        • En Español
        • Sports News
        • Official Clergy Assignments
        • Schools News
  • Commentary
        • Contributors
          • Question Corner
          • George Weigel
          • Elizabeth Scalia
          • Michael R. Heinlein
          • Effie Caldarola
          • Guest Commentary
        • CR Columnists
          • Archbishop William E. Lori
          • Rita Buettner
          • Christopher Gunty
          • George Matysek Jr.
          • Mark Viviano
          • Father Joseph Breighner
          • Father Collin Poston
          • Amen Columns
  • Entertainment
        • Events
        • Movie & Television Reviews
        • Arts & Culture
        • Books
        • Recipes
        • CR for Kids
  • About Us
        • Contact Us
        • Our History
        • Meet Our Staff
        • Photos to own
        • Shop
        • CR Media platforms
        • Electronic Edition
        • Subscribe
  • Advertising
  • Kids
  • Radio/Podcasts
        • Catholic Review Radio
        • Protagonistas de Fe
        • In God’s Image
        • “In Charity and Truth” with Archbishop William E. Lori
  • News Tips
  • Subscribe
Boxes of mifepristone, the first pill given in a medical abortion, are pictured in a Jan. 13, 2023, photo. A federal judge in Texas is poised to rule on whether to suspend the FDA's approval of mifepristone, potentially pulling the drug from the market nationwide. (OSV News photo/Evelyn Hockstein, Reuters)

Federal judge’s pending ruling could block abortion drug from nationwide sale

March 22, 2023
By Kate Scanlon
OSV News
Filed Under: Feature, News, Respect Life, World News

WASHINGTON (OSV News) — A still-pending ruling by a federal judge in Texas could pull an abortion drug from the market across the United States.

A lawsuit by a coalition of pro-life opponents of the drug mifepristone, the first of two drugs used in a medication or chemical abortion, is demanding the U.S. Food and Drug Administration revoke its approval of the drug.

If U.S. District Judge Matthew Kacsmaryk rules in favor of the plaintiffs, he could issue a nationwide injunction on the sale of mifepristone, as requested by the plaintiffs, which would affect even U.S. states where abortion is legal and the drug is permitted under state law.

Another drug used in combination with mifepristone for abortions, called misoprostol, would still be available. Misoprostol is sometimes prescribed by doctors for early miscarriage, but the FDA has not approved the drug for inducing abortion on its own.

A medical assistant at Women’s Reproductive Clinic of New Mexico in Santa Teresa, prepares mifepristone Jan. 13, 2023, the first medication in a medical abortion for a patient. (OSV News photo/Evelyn Hockstein, Reuters)

The Catholic Church teaches that all human life is sacred and must be respected from conception to natural death. It opposes direct abortion as an act of violence that takes the life of the unborn child.

In January, the FDA eased restrictions on the sale of mifepristone, the first of two drugs used in a chemical abortion, permitting their sale at retail pharmacies for the first time. The decision followed the Supreme Court’s decision last year in Dobbs v. Jackson Women’s Health Organization that struck down the 1973 Roe v. Wade decision, after which states moved to restrict or broaden abortion access.

“The FDA approved Mifeprex (mifepristone) more than 20 years ago based on a thorough and comprehensive review of the scientific evidence presented and determined that it was safe and effective for its indicated use,” the agency said on its website.

Proponents of the use of mifepristone for abortion argue the court should keep the FDA regulations in place.

“There’s zero justification for removing this medication from the market that isn’t political,” the ACLU said in a March 15 tweet. “This case should’ve been laughed out of court.”

On its website, the FDA states that mifepristone “is safe when used as indicated and directed” through 10 weeks gestation. The agency’s adverse reaction guidelines for the drug state that “serious and sometimes fatal infections and bleeding occur very rarely.”

Opponents of mifepristone say those risks are more common and more dangerous than proponents of the drug say.

Dr. Ingrid Skop, a board-certified OB-GYN and senior fellow and director of medical affairs at the Charlotte Lozier Institute, told reporters in a March 21 press call that the lawsuit is about “holding the FDA accountable to its own rules and protecting American women and girls from dangerous drugs.”

“Although like approximately 90% of obstetricians, I do not perform elective abortions, I have cared for women in emergency rooms or in my private practice who suffered complications from chemical abortions,” Dr. Skop said. “Because they have been told it’s safer than Tylenol, they are usually surprised and unprepared when complications occur.”

Dr. Skop said the abortion pill is marketed to women as more natural, and as allowing the process to take place “in her own home.” But she said that claim is for “the benefit of the abortion industry, not women.”

“Few physicians are willing to perform abortions,” she said, “so chemical abortions solve staffing problems.”

After a March 15 hearing in Amarillo, Texas, Kacsmaryk did not issue a decision, but indicated his ruling would come as soon as possible.

Read More Respect Life

Planned Parenthood to receive Medicaid funds again as defunding provision expires

Trial begins in California’s lawsuit against pregnancy resource centers’ abortion pill reversal resources

USCCB and pro-life leaders: Abortion pills remain key post-Dobbs challenge

French bishops launch prayer novena ahead of key ‘assisted-dying’ vote

Bishops mark ‘sobering anniversary’ of Canada euthanasia law, call faithful to action

Pope Leo XIV calls defense of life the measure of a nation’s moral greatness in landmark parliament speech

Copyright © 2023 OSV News

Print Print

Primary Sidebar

Kate Scanlon

Click here to view all posts from this author

For the latest news delivered twice a week via email or text message, sign up to receive our free enewsletter.

| MOST POPULAR |

  • Vatican declares SSPX in schism. What does it mean?
  • Two religious sisters from Archdiocese of Baltimore helped shape America
  • After the Vatican declares SSPX in formal schism, what’s next for the Church?
  • In Independence Day Mass, Archbishop Lori calls for continued witness to human dignity
  • The Carrolls of America: Young men, educated in France, influenced a new nation

| Latest Local News |

Radio Interview: Catholicism, religious freedom and the early United States

In Independence Day Mass, Archbishop Lori calls for continued witness to human dignity

The Carrolls of America: Young men, educated in France, influenced a new nation

Two religious sisters from Archdiocese of Baltimore helped shape America

Archdiocese of Baltimore responds to growing immigration enforcement

| Latest World News |

Planned Parenthood to receive Medicaid funds again as defunding provision expires

Pope Leo starts his summer break at Castel Gandolfo with cheerful welcome

Pope visits U.S. embassy July 4 for discussion on peace and freedom, with a side of apple pie

Mass of Thanksgiving for America’s 250th anniversary held at National Shrine in Washington

Pope Leo to pilgrims: ‘Strong; Eucharistic heritage of US must continue as source of renewal, unity’

| Catholic Review Radio |

Footer

Our Vision

Real Life. Real Faith. 

Catholic Review Media communicates the Gospel and its impact on people’s lives in the Archdiocese of Baltimore and beyond.

Our Mission

Catholic Review Media provides intergenerational communications that inform, teach, inspire and engage Catholics and all of good will in the mission of Christ through diverse forms of media.

Contact

Catholic Review
320 Cathedral Street
Baltimore, MD 21201
443-524-3150
mail@CatholicReview.org

 

Social Media

  • Facebook
  • Instagram
  • Twitter
  • YouTube

Recent

  • How do I know if I’m excommunicated due to my past support of the SSPX?
  • Planned Parenthood to receive Medicaid funds again as defunding provision expires
  • Pope Leo starts his summer break at Castel Gandolfo with cheerful welcome
  • Movie Review: ‘Minions & Monsters’
  • Radio Interview: Catholicism, religious freedom and the early United States
  • Pope visits U.S. embassy July 4 for discussion on peace and freedom, with a side of apple pie
  • Mass of Thanksgiving for America’s 250th anniversary held at National Shrine in Washington
  • Pope Leo to pilgrims: ‘Strong; Eucharistic heritage of US must continue as source of renewal, unity’
  • In Independence Day Mass, Archbishop Lori calls for continued witness to human dignity

Search

Membership

Catholic Media Assocation

Maryland-Delaware-DC Press Association

The Associated Church Press

© 2026 CATHOLIC REVIEW MEDIA, ALL RIGHTS RESERVED